International prognostic scoring system for Waldenström macroglobulinemia
Top Cited Papers
Open Access
- 30 April 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 113 (18), 4163-4170
- https://doi.org/10.1182/blood-2008-08-174961
Abstract
Recently, many new drugs have been developed for the treatment of Waldenström macroglobulinemia (WM). To optimize the treatment according to the prognosis and to facilitate the comparison of trials, we developed an International Prognostic Scoring System for WM in a series of 587 patients with clearly defined criteria for diagnosis and for initiation of treatment. The median survival after treatment initiation was 87 months. Five adverse covariates were identified: advanced age (>65 years), hemoglobin less than or equal to 11.5 g/dL, platelet count less than or equal to 100 × 109/L, β2-microglobulin more than 3 mg/L, and serum monoclonal protein concentration more than 7.0 g/dL. Low-risk patients (27%) presented with no or 1 of the adverse characteristics and advanced age, intermediate-risk patients (38%) with 2 adverse characteristics or only advanced age, and high-risk patients (35%) with more than 2 adverse characteristics. Five-year survival rates were 87%, 68%, and 36%, respectively (P < .001). The ISSWM retained its prognostic significance in subgroups defined by age, treatment with alkylating agent, and purine analog. Thus, the ISSWM may provide a means to design risk-adapted studies. However, independent validation and new biologic markers may enhance its significance.Keywords
This publication has 32 references indexed in Scilit:
- Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individualsLeukemia, 2007
- Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myelomaBlood, 2006
- Update on treatment recommendations from the Third International Workshop on Waldenstrom's MacroglobulinemiaBlood, 2006
- Guidelines on the management of Waldenström macroglobulinaemia*British Journal of Haematology, 2006
- Diagnosis and Management of Waldenstrom's MacroglobulinemiaJournal of Clinical Oncology, 2005
- Prognostic Validation of the International Classification of Immunoglobulin M Gammopathies: A Survival Advantage for Patients with Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance?Clinical Cancer Research, 2005
- Prognostic factors in symptomatic Waldenstrom's macroglobulinemiaSeminars in Oncology, 2003
- Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 casesBritish Journal of Haematology, 2001
- Waldenstrom's macroglobulinemiaBlood, 1994
- Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases.Journal of Clinical Oncology, 1993